| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/14651858.CD008056.PUB3 |
| P8608 | Fatcat ID | release_eu47jxkcgvdppkj4gympy3b6nu |
| P698 | PubMed publication ID | 26758498 |
| P50 | author | Taixiang Wu | Q67189809 |
| Bi Rong Dong | Q87466239 | ||
| P2093 | author name string | Guan J Liu | |
| Jirong Yue | |||
| Ming Yang | |||
| Xiaomei Chen | |||
| P2860 | cites work | Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections | Q43996924 |
| Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection | Q44320945 | ||
| Effect of Linezolid versus Vancomycin on Length of Hospital Stay in Patients with Complicated Skin and Soft Tissue Infections Caused by Known or Suspected Methicillin-Resistant Staphylococci: Results from a Randomized Clinical Trial | Q44439560 | ||
| Linezolid versus vancomycin in the treatment of known or suspected resistant Gram-positive infections in neonates | Q44603323 | ||
| Linezolid for the treatment of complicated skin and skin structure infections in children | Q44603331 | ||
| Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children | Q44603334 | ||
| Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia | Q44647040 | ||
| Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin | Q44721295 | ||
| Linezolid eradicates MRSA better than vancomycin from surgical-site infections | Q45201834 | ||
| Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus | Q46429720 | ||
| Linezolid for the treatment of infections caused by Gram-positive pathogens in China | Q46477911 | ||
| Cost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in Germany | Q46626102 | ||
| Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies | Q46728767 | ||
| Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA). | Q46805282 | ||
| Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004). | Q53239767 | ||
| Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). | Q54453191 | ||
| A novel antimicrobial agent joins the battle against resistant bacteria | Q74587568 | ||
| Managing skin and soft tissue infections: expert panel recommendations on key decision points | Q79353901 | ||
| A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft-tissue infections caused by suspected or confirmed methicillin-resistant Staphylococcus aur | Q80496702 | ||
| Red man syndrome | Q21195101 | ||
| The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning | Q24652742 | ||
| Measuring inconsistency in meta-analyses | Q27860655 | ||
| Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials | Q27860735 | ||
| Impact of patient characteristics and infection type on clinical outcomes of patients who received linezolid or vancomycin for complicated skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus: a pooled data analys | Q30721622 | ||
| Linezolid: an oxazolidinone antimicrobial agent | Q33336987 | ||
| Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan | Q33376899 | ||
| Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials | Q33378032 | ||
| Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis | Q33387451 | ||
| Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections | Q33836490 | ||
| The existence of publication bias and risk factors for its occurrence | Q34373168 | ||
| Practice guidelines for the diagnosis and management of skin and soft-tissue infections | Q34460523 | ||
| Vancomycin: a history | Q34472263 | ||
| Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer | Q34489730 | ||
| Efficacy and safety of linezolid in the treatment of skin and soft tissue infections | Q34781663 | ||
| Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study | Q34900607 | ||
| Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infections | Q34922533 | ||
| A practical guide to the treatment of complicated skin and soft tissue infections | Q35166376 | ||
| Safety and efficacy of glycopeptide antibiotics | Q36063042 | ||
| Epidemiology of severe Streptococcus pyogenes disease in Europe. | Q36747672 | ||
| Treatment challenges in the management of complicated skin and soft-tissue infections | Q37069446 | ||
| Cost-effectiveness analysis of linezolid vs. vancomycin in treating methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections using a decision analytic model. | Q37394892 | ||
| Linezolid versus vancomycin for MRSA skin and soft tissue infections (systematic review and meta-analysis). | Q37628774 | ||
| Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials | Q37630016 | ||
| Does empiric antibiotic therapy change MRSA [corrected] hand infection outcomes? Cost analysis of a randomized prospective trial in a county hospital. | Q38199907 | ||
| Impact of weight on treatment efficacy and safety in complicated skin and skin structure infections and nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus | Q38445030 | ||
| Vancomycin in the treatment of meticillin-resistant Staphylococcus aureus (MRSA) infection: End of an era? | Q39016434 | ||
| Is linezolid superior to vancomycin for complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus? | Q42424814 | ||
| Cost-effectiveness of linezolid and vancomycin in the treatment of surgical site infections | Q42610398 | ||
| Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus | Q42652703 | ||
| Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections | Q42686505 | ||
| Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008. | Q43242321 | ||
| Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial | Q43546278 | ||
| Linezolid resistance in a clinical isolate of Staphylococcus aureus | Q43690311 | ||
| The role of diabetes mellitus in the treatment of skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus: results from three randomized controlled trials | Q43795846 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | linezolid | Q411377 |
| vancomycin | Q424027 | ||
| P577 | publication date | 2016-01-07 | |
| P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
| P1476 | title | Linezolid versus vancomycin for skin and soft tissue infections |
| Q40063090 | Bacterial skin and soft tissue infections |
| Q47611899 | Clinical Pharmacokinetics and Pharmacodynamics of Oxazolidinones |
| Q96303500 | Dynamic Changes of Staphylococcus aureus Susceptibility to Vancomycin, Teicoplanin, and Linezolid in a Central Teaching Hospital in Shanghai, China, 2008-2018 |
| Q47327608 | Efficacy and safety of linezolid compared with other treatments for skin and soft-tissue infections: a meta-analysis |
| Q55368160 | Linezolid: a review of its properties, function, and use in critical care. |
| Q64064755 | Network meta-analysis and pharmacoeconomic evaluation of antibiotics for the treatment of patients infected with complicated skin and soft structure infection and hospital-acquired or ventilator-associated penumonia |
| Q40052636 | Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: a systematic review, network meta-analysis and cost analysis |
| Q40068002 | Spread of Tst-Positive Staphylococcus aureus Strains Belonging to ST30 Clone among Patients and Healthcare Workers in Two Intensive Care Units |
Search more.